Table 1.
Selected overview of running clinical trials
| Referencea | Phase | Statusb | Interventionc | Cancer type |
|---|---|---|---|---|
| CD40 | ||||
| NCT03424005 | 1b/2 | ANR | Selicrelumab#1, atezolizumab, bevacizumab | Breast cancer |
| NCT03555149 | 1b/2 | ANR | Selicrelumab#1, bevacizumab, atezolizumab | Colorectal cancer |
| NCT03193190 | 1b/2 | R | Nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, fluorouracil, atezolizumab, cobimetinib, PEGPH2O, BL-8040, selicrelumab#1, bevacizumab, RO6874281, AB928, tiragolumab, tocilizumab | Pancreatic ductal adenocarcinoma |
| NCT04364230 | 1/2 | R | Peptide vaccine, polyICLC, CDX-1140#2 | Melanoma |
| NCT04536077 | 2 | R | CDX-1140#2; CCX-301, CDX-1140#2 |
Pancreatic cancer |
| NCT04616248 | 1 | NYR | CDX-1140#2, CCX-301, radiotherapy, poly-ICLC | Breast cancer |
| NCT04491084 | 1/2 | R | CDX-1140#2, CCX-301, stereotactic body radiation therapy | NSCLC |
| NCT04520711 | 1/1b | R | TCR-transduced T cells, CDX-1140#2, pembrolizumab | Epithelial cancer |
| NCT03502330 | 1 | ANR | APX005M#3, cabiralizumab; APX005M#3, cabiralizumab, nivolumab |
Melanoma NSCLC Renal cell carcinoma |
| NCT03719430 | 2 | R | APX005M#3, doxorubicin | Soft-tissue carcinoma |
| NCT03165994 | 2 | ANR | APX005M#3, radiation, paclitaxel, carboplatin, surgical resection | Esophageal cancer |
| NCT02706353 | 2 | R | APX005M#3, pembrolizumab | Melanoma |
| NCT03389802 | 1 | R | APX005M#3 | Pediatric CNS tumors |
| NCT04337931 | 2 | ANR | APX005M#3 | Melanoma |
| NCT04130854 | 2 | ANR | mFOLFOX, radiation, APX005M#3 | Rectal adenocarcinoma |
| NCT04495257 | 1 | R | APX005M#3, nivolumab, ipilimumab | Melanoma Renal cell carcinoma |
| NCT02600949 | 1 | R | Imiquimod, pembrolizumab, sotigalimab#3, peptide vaccine | Colorectal adenocarcinoma Pancreatic ductal adenocarcinoma |
| NCT02376699 | 1 | ANR | SEA-CD40#4; SEA-CD40#4, pembrolizumab SEA-CD40#4, pembrolizumab, gemcitabine, nab-paclitaxel |
B Cell lymphoma Follicular lymphoma Hodgkin lymphoma Large B Cell, diffuse lymphoma Non-Hodgkin lymphoma NSCLC Melanoma Squamous cell carcinoma Pancreatic ductal adenocarcinoma |
| CD137 | ||||
|---|---|---|---|---|
| JapicCTI-205153 | 1 | R | STA551#5; STA551#5, atezolizumab |
Advanced/metastatic solid tumors |
| NCT04121676 | 1 | R | AGEN2373#6; AGEN2373#6, botensilimab |
Advanced/metastatic solid tumors |
| NCT04903873 | 1/2 | R | EU101#7 | Colorectal cancer NSCLC |
| NCT04501276 | 1 | R | ADG116, ADG106#8 | Advanced/metastatic solid tumors |
| NCT03792724 | 1/2 | NYR | Urelumab#9, nivolumab | PD-1/PD-L1 sensitive tumors |
| NCT02845323 | 2 | ANR | Nivolumab, urelumab#9 | Urothelial cancer |
| NCT03431948 | 1 | ANR | Nivolumab, urelumab#9, radiation | Advanced solid tumors |
| NCT02451982 | 2 | R | Cyclophosphamide, pancreatic tumor vaccine, nivolumab, urelumab#9 | Pancreatic cancer |
| NCT02652455 | 1 | ANR | Nivolumab, urelumab#9, cyclophosphamide, fludarabine, aldesleukin, autologous tumor-infiltrating lymphocytes | Melanoma |
| NCT02658981 | 1 | ANR | Urelumab#9; Nivolumab, urelumab#9; Anti-LAG-3 monoclonal antibody BMS 986016, nivolumab, urelumab#9 |
Glioblastoma Gliosarcoma Recurrent brain neoplasm |
| NCT03318900 | 1 | ANR | Aldesleukin, CD8-positive T-lymphocytes, cyclophosphamide, utomilumab#10 | Ovarian cancer |
| NCT03414658 | 2 | R | Vinorelbine, trastuzumab, avelumab, utomilumab#10; Trastuzumab, avelumab, utomilumab#10 |
Breast cancer |
| NCT03290937 | 1 | ANR | Cetuximab, irinotecan hydrochloride, utomilumab#10 | Colorectal cancer |
| NCT03217747 | 1/2 | ANR | Avelumab, utomilumab#10; Avelumab, ivuxolimab, utomilumab#10; Avelumab, utomilumab#10, radiation; Avelumab, ivuxolimab, utomilumab#10, radiation |
Castration-resistant prostate cancer |
| NCT02554812 | 1/2 | ANR | Avelumab, utomilumab#10; Avelumab, utomilumab#10, PF-04518600; Avelumab, utomilumab#10; Avelumab, utomilumab#10, vidutolimod |
Bladder cancer Gastric cancer Head and neck squamous cell carcinoma Melanoma NSCLC Ovarian cancer |
| NCT03971409 | 2 | R | Avelumab, utomilumab#10 | Breast cancer |
| NCT05059522 | 3 | R | Avelumab, utomilumab#10, vidutolimod, PF04518600 | NSCLC Ovarian cancer Solid tumors Urothelial cancer |
| Interferon-γ/interleukin 12 | ||||
|---|---|---|---|---|
| NCT03112590 | 1/2 | ANR | INF-γ, paclitaxel, tastuzumab, pertuzumab, post-therapy surgery | Breast cancer |
| NCT03132675 | 2 | R | Tavokinogene telseplasmid#11, pembrolizumab, immunopulse | Melanoma |
| NCT03567720 | 2 | R | Tavokinogene telseplasmid#11, pembrolizumab, immunopulse Tavokinogene telseplasmid#11, pembrolizumab, immunopulse, nab-paclitaxel |
Breast cancer |
| NCT04526730 | 2 | R | Tavokinogene telseplasmid#11, nivolumab, immunopulse | Melanoma |
| NCT02555397 | 1 | ANR | Ad5-yCD/mutTKSR39rep-hIL12#12 | Prostate cancer |
| NCT04911166 | 1 | R | ADV/IL-12 gene therapy#13, atezolizumab | NSCLC |
| NCT03030378 | 1 | R | Edodekin alfa#14, pembrolizumab | Metastatic solid tumors |
| NCT01468896 | 1/2 | ANR | Cetruximab, edodekin alfa#14 | Head and neck squamous cell carcinoma |
| NCT04235777 | 1 | 1 | M7824#30, M9241#15; M7824#30, M9241#15, stereotactic body radiation therapy |
Urogenital cancer Urothelial cancer |
| NCT05361798 | 2 | R | M9241#15, stereotactic body radiation therapy | Prostate cancer |
| NCT04633252 | 1/2 | R | Androgen deprivation therapy, prednisone, M7824#30, docetaxel, M9241#15 | Prostate cancer |
| NCT05286814 | 2 | R | Floxuridine, 5-fluorouracil, irinotecan, oxaliplatin, leucovorin, M9241#15, gemcitabine, dexamethasone | Colorectal cancer Intrahepatic cholangiocarcinoma |
| NCT04708470 | 1/2 | R | Bintrafusp alfa#30, NHS-IL12#15, entinostat | Anal cancer Cervical cancer Colon cancer Neck cancer Oropharyngeal cancer Penile cancer Vaginal cancer Vulvar cancer |
| NCT04303117 | 1/2 | R | NHS-IL12#15, M7824#30 | Kaposi sarcoma |
| NCT04491955 | 2 | R | CV301, MSB0011359C#30, N-803#29; CV301, MSB0011359C#30, N-803#29, NHS-IL12#15 |
Colorectal cancers Small bowel cancers |
| NCT04287868 | 1/2 | R | PDS0101, M7824#30, NHS-IL12#15 | Anal cancer Cervical cancer HPV cancers Oropharyngeal cancer Penile cancer Rectal cancer Vaginal cancer Vulvar cancer |
| NCT02498912 | 1 | ANR | 4H11-28z/fIL-12/EGFRt+ genetically modified T cells#16 | Solid tumors |
| NCT04613492 | 1 | R | MEDI9253#17, durvalumab | Advanced/metastatic solid tumors |
| NCT03439085 | 2 | ANR | MEDI0457#18, durvalumab | HPV cancer |
| NCT04471987 | 1 | R | IL12-L19L19#19 | Advanced/metastatic solid tumors |
| NCT03393884 | 1/2 | R | GEN-1#20, carboplatin, paclitaxel | Ovarian cancer Fallopian tube cancer Peritoneal cancer |
| NCT05352750 | 1 | R | SON-1010#21 | Advanced solid tumors |
| NCT04388033 | 1/2 | R | Dendritic cell/tumor fusion vaccine, IL-12, temozolomide | Glioblastoma |
| NCT05077033 | 1 | R | phIL12 GET#22 | Basal cell carcinoma |
| NCT05095441 | 1 | NYR | C5252#23 | Glioblastoma |
| Interleukin 4 | ||||
|---|---|---|---|---|
| NCT05013450 | 1/2 | R | Dupilumab#24, PD-1/PD-L1 blockade | NSCLC |
| Interleukin 15/interleukin 15 receptor | ||||
|---|---|---|---|---|
| NCT04491955 | — | — | Multiple target combination—details on clinical trial see section Interferon-γ/interleukin 12 | — |
| NCT04261439 | 1 | R | NIZ985#25, spartalizumab; NIZ985#25, spartalizumab, tislelizumab |
Advanced solid tumors Melanoma NSCLC |
| NCT04234113 | 1 | R | SO-C101#26; SO-C101#26, pembrolizumab |
Anal cancer Thyroid cancer Bladder cancer Biliary tract cancer Cervical cancer Cutaneous squamous cell carcinoma Gastric cancer Head and neck squamous cell carcinoma Hepatocellular carcinoma Melanoma Mesothelioma Merkel cell carcinoma Microsatellite instability high NSCLC Ovarian cancer Renal cell carcinoma Small-cell lung cancer Thymic cancer Triple-negative breast cancer |
| NCT05619172 | 2 | NYR | SOT101#26, cetuximab | Colorectal cancer |
| NCT05256381 | 2 | R | SOT101#26, pembrolizumab | Castration-resistant prostate cancer Colorectal cancer Cutaneous squamous cell carcinoma Hepatocellular carcinoma NSCLC Ovarian cancer |
| NCT04250155 | 1 | R | XmAb24306#27; Atezolizumab+ XmAb24306#27 |
Advanced/metastatic/recurrent solid tumors |
| NCT04616196 | 1/2 | R | NKTR-255#28, cetuximab | Anal squamous cell carcinoma Cervical cancer Colorectal cancer Cutaneous squamous cell carcinoma Head and neck squamous cell carcinoma |
| NCT05327530 | 2 | R | Avelumab+NKTR-255#28 | Urothelial cancer |
| NCT05445882 | 2 | NYR | N-803#29; N-803#29, BN-Brachyury; N-803#29, bintrafusp alfa#30 |
Castration-resistant prostate cancer |
| NCT04847466 | 2 | R | N-803#29, pembrolizumab, PD-L1 t-haNK | Gastroesophageal junction cancer Head and neck squamous cell carcinoma |
| NCT03022825 | 2/3 | R | N-803#29, intravesical Bacillus Calmette–Guerin | Bladder cancer |
| NCT05096663 | 2/3 | R | N-803#29, pembrolizumab | NSCLC |
| NCT02138734 | 1/2 | R | N-803#29, intravesical Bacillus Calmette–Guerin | Bladder cancer |
| NCT04247282 | 1/2 | ANR | M7824#30, N803#29+TriAd vaccine | Head and neck cancer |
| NCT03493945 | 1/2 | R | M7824#30, N803#29; M7824#30, N803#29, MVA-BN-Brachyury, FPV-Brachyury; M7824#30, N803#29, MVA-BN-Brachyury, FPV-Brachyury, epacadostat |
Advanced/metastatic solid tumors Prostate cancer |
| NCT03520686 | 3 | ANR | N-803#29, pembrolizumab; N-803#29, carboplatin, nab-paclitaxel, pembrolizumab; N-803#29, cisplatin or carboplatin, pembrolizumab, pemetrexed |
NSCLC |
| NCT04927884 | 1/2 | ANR | N-803#29, PD-L1 t-haNK, sacituzumab Govitecan-Hziy, cyclophosphamide | Triple-negative breast cancer |
| NCT03228667 | 2 | ANR | N-803#29, pembrolizumab; N-803#29, nivolumab; N-803#29, atezolizumab; N-803#29, avelumab; N-803#29, durvalumab; N-803#29, pembrolizumab, PD-L1 t-haNK; N-803#29, nivolumab, PD-L1 t-haNK; N-803#29, atezolizumab, PD-L1 t-haNK; N-803#29, avelumab, PD-L1 t-haNK; N-803#29, durvalumab, PD-L1 t-haNK |
Cervical cancer Colorectal cancer NSCLC Gastric cancer Head and neck squamous cell carcinoma Hepatocellular carcinoma Melanoma Merkel cell carcinoma Microsatellite instability Mismatch repair deficiency Small-cell lung cancer Renal cell carcinoma Urothelial cancer |
| Transforming growth factor beta | ||||
|---|---|---|---|---|
| NCT04247282 | — | — | Multiple target combination—details on clinical trial see section Interleukin 15/interleukin 15 receptor | — |
| NCT03493945 | — | — | Multiple target combination—details on clinical trial see section Interleukin 15/interleukin 15 receptor | — |
| NCT04491955 | — | — | Multiple target combination—details on clinical trial see section Interferon-γ/interleukin 12 | — |
| NCT04303117 | — | — | Multiple target combination—details on clinical trial see section Interferon-γ/interleukin 12 | — |
| NCT04235777 | — | — | Multiple target combination—details on clinical trial see section Interferon-γ/interleukin 12 | — |
| NCT04287868 | — | — | Multiple target combination—details on clinical trial see section Interferon-γ/interleukin 12 | — |
| NCT04633252 | — | — | Multiple target combination—details on clinical trial see section Interferon-γ/interleukin 12 | — |
| NCT04708470 | — | — | Multiple target combination—details on clinical trial see section Interferon-γ/interleukin 12 | — |
| NCT05445882 | — | — | Multiple target combination—details on clinical trial see section Interleukin 15/interleukin 15 receptor | — |
| NCT04574583 | 1/2 | ANR | SX-682, M7824#30, MVA-BN-CV301, FPV-CV301 | Advanced/metastatic cancer Head and neck squamous cell carcinoma Triple-negative breast cancer |
| NCT04432597 | 1/2 | R | PRGN-2009, M7824#30 | Anal cancer Cervical cancer HPV-positive solid cancer Oropharyngeal cancer Penile cancer Rectal cancer Vaginal cancer Vulvar cancer |
| NCT04297748 | 1/2 | R | 89Zirconium-M7824, M7824#30 | NSCLC |
| NCT04417660 | 2 | R | M7824#30 | Thymic cancer Recurrent thymoma |
| NCT03436563 | 1/2 | ANR | M7824#30 | Colorectal adenocarcinoma |
| NCT04835896 | 1/2 | NYR | M7824#30, paclitaxel | Gastric cancer |
| NCT03427411 | 2 | ANR | M7824#30 | Anal cancer Cervical cancer HPV-positive solid tumors Oropharyngeal cancer Penile cancer Vaginal cancer |
| NCT03631706 | 3 | ANR | M7824#30 | NSCLC |
| NCT05005429 | 2 | R | M7824#30 | Mesothelioma |
| NCT03620201 | 1 | ANR | M7824#30 | Breast cancer |
| NCT03554473 | 1/2 | R | M7824#30, temozolomide; M7824#30, topotecan |
Small-cell lung cancer |
| NCT03840902 | 2 | ANR | M7824#30, etoposide, pemetrexed, carboplatin, paclitaxel, cisplatin, intensity-modulated radiation therapy | NSCLC |
| NCT04066491 | 2/3 | ANR | M7824#30, gemcitabine, cisplatin | Biliary tract cancer |
| NCT05145569 | 1 | NYR | Carboplatin AUC 5 and paclitaxel, M7824#30 | Ovarian cancer |
| NCT03315871 | 2 | R | PROSTVAC-V, PROSTVAC-F, M7824#30, CV301 | Prostate cancer |
| NCT04551950 | 1 | ANR | M7824#30, carboplatin, paclitaxel, bevacizumab, cisplatin; M7824#30, carboplatin, paclitaxel, cisplatin; M7824#30, cisplatin, radiotherapy |
Cervical cancer |
| NCT04481256 | n.a. | R | Radiatin, bintrafusp alfa#30, paclitaxel, carboplatin | Squamous cell carcinoma |
| NCT04246489 | 2 | ANR | Bintrafusp alfa#30 | Cervical cancer |
| NCT05061823 | 3 | R | Bintrafusp alfa#30 | Cancer |
| NCT05012098 | 2 | R | Bintrafusp alfa#30 | Esthesioneuroblastoma |
| NCT04595149 | 2 | R | Bintrafusp alfa#30 | Esophageal cancer |
| NCT04349280 | 1 | ANR | Bintrafusp alfa#30 | Urothelial cancer |
| NCT04396535 | 2 | ANR | Bintrafusp alfa#30, docetaxel | NSCLC |
| NCT04708067 | 1 | R | Bintrafusp alfa#30, hypofractionated radiation therapy | Intrahepatic cholangiocarcinoma |
| NCT04874311 | 2 | R | Bintrafusp alfa#30, doxorubicin | Soft-tissue sarcoma |
| NCT04396886 | 2 | ANR | Bintrafusp alfa#30 | Nasopharyngeal carcinoma Non-keratinizing carcinoma |
| NCT04789668 | 1/2 | ANR | Bintrafusp alfa#30, pimasertib | Breast cancer Hematopoietic and lymphoid cell neoplasm Melanoma Neoplasm in the brain NSCLC |
| NCT04878250 | 2 | NYR | Bintrafusp alfa#30 | Urothelial cancer |
| NCT04457778 | 1 | R | M6223, bintrafusp alfa#30 | Metastatic solid tumors |
| NCT02723955 | 1 | ANR | Feladilimab, bintrafusp alfa#30 | Colorectal cancer Deficient mismatch repair tumor Esophageal cancer Epstein–Barr positive tumor Head and neck carcinoma HPV-positive tumor Melanoma Mesothelioma Microsatellite instability-high tumor NSCLC Prostate cancer Squamous cell carcinoma Urothelial cancer |
| NCT03834662 | 1 | ANR | AVID200#31 | Advanced/metastatic solid tumors |
| NCT05537051 | 1 | NYR | PM1021, PM8001#32 | Advanced solid tumors |
| NCT05028556 | 1 | R | Y101D#33 | Metastatic/advanced solid tumors |
| NCT05381935 | 1 | NYR | ES014#34 | Advanced solid tumors |
| NCT04862767 | 1 | R | TASO-001#35, aldesleukin | Solid tumors |
| Histamine | ||||
|---|---|---|---|---|
| NCT04165096 | 2 | ANR | Pembrolizumab, MK-5890, diphenhydramine#36, acetaminophen | NSCLC |
| NCT04863950 | 2 | R | Lomustine, imipramine hydrochloride#37 | Glioblastoma |
| NCT03253289 | 1 | R | Meclizine#38 | Hepatocellular carcinoma |
| 2022-001284-27 | 2 | ANR | Fexofenadine hydrochloride#39, pembrolizumab | NSCLC |
| Vitamin E | ||||
|---|---|---|---|---|
| NCT04245865 | 2 | R | Fluorouracil, calcium folinate, oxaliplatin, bevacizumab, capecitabine, tocotrienol | Colorectal cancer |
| NCT02705300 | 2 | ANR | FOLFOXIRI, tocotrienol | Colorectal cancer |
| NCT04175470 | 2 | R | Bevacizumab, tocotrienol | Ovarian cancer |
CNS, central nervous system; EGFR, epidermal growth factor receptor; HPV, human papillomavirus; IL, interleukin; NSCLC, non-small-cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.
NCT identifiers refer to trials registered at www.clinicaltrials.gov, https://rctportal.niph.go.jp, or https://www.clinicaltrialsregister.eu/ctr-search/search/.
Status: R, recruiting; ANR, active, not recruiting; NYR, not yet recruiting. Intervention. #1 Selicrelumab—fully human IgG2 agonistic monoclonal antibody (mAb) to CD40. #2 CDX-1140—fully human IgG2 agonistic mAb to CD40. #3 APX005M (alias sotigalimab)—is a humanized rabbit IgG1 agonistic mAb to CD40.#4 SEA-CD40 (alias dacetuzumab)—is a humanized IgG1, non-fucosylated agonistic mAb to CD40. #5 STA551—human IgG1/lambda agonist switch antibody to CD137 with binding only in the presence of ATP. #6 AGEN2373—fully human IgG1 agonistic mAb to CD137. #7 EU101—fully humanized IgG1 agonistic mAb to CD137. #8 ADG106—fully human IgG4 agonistic mAb to CD137. #9 Urelumab—fully human IgG4 agonistic mAb to CD137. #10 Utomilumab—fully human IgG2 agonistic mAb to CD137. #11 Tavokinogene telseplasmid—intratumoral injected plasmid-encoding IL-12 by electroporation using the immunopulse. #12 Ad5-yCD/mutTKSR39rep-hIL12—replication-competent oncolytic adenovirus encoding IL-12 gene, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39). #13 ADV/IL-12 gene therapy—adenoviral-mediated interleukin-12. #14 Edodekin alfa—recombinant IL-12. #15 M9241 (alias NHS-IL12)—two IL-12 molecules fused to a human IgG1-recognizing DNA/histone complexes. #16 4H11-28z/fIL-12/EGFRt+ genetically modified T cells—genetically modified autologous T cells transduced with a retroviral vector expressing a chimeric antigen receptor targeting the human tumor-associated antigen MUC16ecto and encoding IL-12 fused to the signaling domain of the zeta chain of the TCR/CD3 complex (28z) and a truncated form of the human epidermal growth factor receptor (EGFRt). #17 MEDI9253—oncolytic viral agent containing the oncolytic, live-attenuated, replication-competent strain of the avian paramyxovirus Newcastle disease virus (NDV) engineered to include a transgene encoding IL-12. #18 MEDI0457—DNA Plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine. #19 IL12-L19L19—fusion protein of recombinant IL-12 with human mAb L19 specific for the extra-domain B of fibronectin in tandem diabody format. #20 GEN1—IL-12 plasmid with PEG-PEI-cholesterol lipopolymer. #21 SON-1010—single-chain human IL12 linked to a single-chain variable region antibody fragment. #22 phIL12 GET—intratumoral gene transfer of plasmid coding for IL-12. #23 C5252—genetically engineered oncolytic herpes simplex virus type 1 (oHSV-1) expressing the IL-12 and an antibody directed against PD-1.#24 Dupilumab—fully human IgG4 antagonistic dimeric mAb to IL-4 receptor α/γc and IL-4 receptor α/IL-13 receptor α. #25 NIZ985—recombinant IL-15/IL-15Rα heterodimer.#26 SO-C101 (alias SOT101)—fusion protein of recombinant IL-15 linked to IL-15Rα sushi (cytokine-binding) domain. #27 XmAb24306—recombinant IL-15/IL-15Rα cytokine fusion complex. #28 NKTR-255—polyethylene glycol-conjugated recombinant human IL-15 agonist. #29 N-803—mutated form of the cytokine IL-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc). #30 M7824 (alias bintrafusp alfa, MSB0011359C)—bifunctional fusion protein of human IgG1 mAb against PD-L1 fused with two extracellular domains of TGF-β receptor type II. #31 AVID200—receptor ectodomain trap. #32 PM8001—bifunctional protein composed of the extracellular domain of the TGF-β receptor type II receptor fused to a humanized anti-PD-L1 IgG1 single-domain antibody. #33 Y101D—recombinant anti-PD-L1 and TGF-β bispecific antibody. #34 ES014—anti-CD39 and TGF-β bispecific antibody. #35 TASO-001—TGF-β2 targeting antisense oligonucleotide. #36 Diphenhydramine—H1-antihistamine antagonist. #37 Imipramine hydrochloride—H1-antihistamine antagonist. #38 Meclizine—H1-antihistamine antagonist. #39 Fexofenadine hydrochloride—H1-antihistamine antagonist.